This study demonstrated that atezolizumab plus nab-paclitaxel combination therapy prolonged progression-free survival among patients with metastatic triple-negative breast cancer (TNBC) in both the intention-to-treat population and the PD-L1-positive subgroup, and it exhibited good safety (Schmid et al., 2018). Here, CD274 is linked to triple-negative breast carcinoma.